NewsHK
Zealand, the biotech whose share price has become an informal gauge of sentiment across the weight-loss drug sector, is recording a visible shift in investor positioning.
One of its experimental medicines has lost market traction, but the broader weight-loss trade is not unwinding — attention is rotating toward amylin-based therapies, which investors are beginning to treat as the sector's designated growth frontier.
When a Drug Loses the Crowd The pullback from one of Zealand's pipeline candidates follows a pattern the biotech sector knows well.
An experimental drug builds investor conviction early, draws capital, compresses future upside into the current price, and then softens as the market revisits its probability estimates.
Keep reading